TRACON Pharmaceutical (TCON) Offers Additional Detail on Janssen Licensing Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.
September 28, 2016 8:02 AM EDTStrategic Transaction Validates TRACONs Unique Clinical Development Capabilities
$5 Million Equity Investment Strengthens TRACONs Balance Sheet
SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet agerelated macular degeneration and fibrotic diseases, today announced a strategic licensing collaboration with Janssen Pharmaceutica N.V. (Janssen) for two novel oncology assets from Janssens early development portfolio, with Janssen retaining certain rights to potentially reacquire the programs. Johnson & Johnson... More
